Monday, February 11, 2013

• ACT’s Chief Scientific Officer Robert Lanza, MD, Appointed Editor-in-Chief of BioResearch Open Access JournalBusiness Wire (Mon, Feb 11)
• 2 Stem Cell Research Pioneers And Where They Are Todayat Seeking Alpha (Mon, Feb 11)
• ACT’s Clinical Partner Receives FDA Approval to Initiate Clinical Trial Using the Company’s hESC-derived Cells to Treat Severe MyopiaBusiness Wire (Mon, Feb 11)

Friday, February 8, 2013

• Advanced Cell Technology to Present at 15th Annual BIO CEO & Investor ConferenceBusiness Wire (Fri, Feb 8)
• Insight On Advanced Cell Technology: An Interview With Gary Rabin, Chairman And CEOat Seeking Alpha (Fri, Feb 8)

Friday, January 25, 2013

• ADVANCED CELL TECHNOLOGY, INC. Files SEC form 8-K, Unregistered Sale of Equity SecuritiesEDGAR Online (Fri, Jan 25)

Tuesday, January 22, 2013

• Patients with Better Vision to be Enrolled in ACT’s Clinical Trials for Macular DegenerationBusiness Wire (Tue, Jan 22)

Friday, January 18, 2013

• ADVANCED CELL TECHNOLOGY, INC. Files SEC form 8-K/A, Entry into a Material Definitive AgreementEDGAR Online (Fri, Jan 18)

Thursday, January 17, 2013

• ADVANCED CELL TECHNOLOGY, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct FEDGAR Online (Thu, Jan 17)
• Advanced Cell Technology Announces Settlement of LitigationBusiness Wire (Thu, Jan 17)

Wednesday, January 9, 2013

• Stem Cell Companies For Consideration In 2013at Seeking Alpha (Wed, Jan 9)

Tuesday, January 8, 2013

• Advanced Cell Technology Achieves Clinical MilestoneBusiness Wire (Tue, Jan 8)
• Looking Beyond The JPM Global Healthcare Conference: More Biotech Than Meets The Eyeat Seeking Alpha (Tue, Jan 8)

Monday, January 7, 2013

• Advanced Cell Technology to Present at Biotech Showcase™ 2013Business Wire (Mon, Jan 7)

Wednesday, January 2, 2013

• Stem Cells, Dr. Oz And A Potentially Lucrative Investment Opportunityat Seeking Alpha (Wed, Jan 2)

Thursday, December 20, 2012

• New Scientist Magazine Selects ACT’s Induced Pluripotent Stem (iPS) Cell-Derived Human Platelet Program As One of ‘10 Ideas That Will Shape The Year’Business Wire (Thu, Dec 20)

Wednesday, December 19, 2012

• Advanced Cell Technology Elects Not to Complete Reverse SplitBusiness Wire (Wed, Dec 19)

Monday, December 17, 2012

• ACT Announces Completion of Higher-Dosage Cohort in European Clinical Trial for Stargardt’s Macular DystrophyBusiness Wire (Mon, Dec 17)

Thursday, December 6, 2012

• ACTC And The Ghosts Of Christmasat Seeking Alpha (Thu, Dec 6)

Monday, December 3, 2012

• Advanced Cell Technology to Participate on Panels and Host Experts Luncheon at 2012 World Stem Cell SummitBusiness Wire (Mon, Dec 3)

Wednesday, November 28, 2012

• ACT Announces Completion of Higher-Dosage Cohort in Both U.S. Clinical TrialsBusiness Wire (Wed, Nov 28)

Monday, November 12, 2012

• Pennyland Biopharma Stocks: Value Or Value-Traps?at Seeking Alpha (Mon, Nov 12)

Saturday, November 10, 2012

• Advanced Cell Technology 's CEO Discusses Q3 2012 Results - Earnings Call Transcriptat Seeking Alpha (Sat, Nov 10)

Thursday, November 8, 2012

• ADVANCED CELL TECHNOLOGY, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online (Thu, Nov 8)
• Advanced Cell Technology Announces Interim Data from Its Three Ongoing Macular Degeneration TrialsBusiness Wire (Thu, Nov 8)

Add ACTC News to My Yahoo!